The Pharma Letter8h
Second FDA approval for BeiGene’s Tevimbra in 2024
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...
The Pharma Letter8h
Inmagene takes back-door route to Nasdaq listing
Inmagene Biopharmaceuticals merges with Ikena Oncology to form InmageneBio, focusing on IMG-007, an OX40-targeting antibody ...
The Pharma Letter8h
AusperBio raises $73 million to advance hepatitis B therapy
AusperBio raises $73 million in series B funding to advance Phase II trials of AHB-137, its antisense oligonucleotide therapy ...
The Pharma Letter10h
Akums in long-term deal to supply oral drugs to Europe
Akums secures a strategic deal to manufacture and supply oral liquid formulations for a global pharma company in Europe. The ...
The Pharma Letter10h
Mankind Pharma and Innovent partner for sintilimab
Mumbai, India-based Mankind Pharma has entered into a partnership with China’s Innovent Biologics for exclusively licensing ...
The Pharma Letter9h
Kaken inks license agreement for STAT6 Inhibitor
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for ...
The Pharma Letter11h
FDA label changes for transmucosal buprenorphine products
The US Food and Drug Administration (FDA) has issued the Federal Register notice, Modifications to Labeling of ...
The Pharma Letter22h
Takeda’s Hyqvia approved as first-of-kind immunoglobulin therapy in Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human ...